Incidence and survival of hepatocellular carcinoma in type 2 diabetes with cirrhosis who were treated with Metformi

Not Applicable

Completed

• Conditions: Hepatocellular carcinoma in type 2 diabetes with cirrhosis.; Hepatocellular carcinoma; type 2 diabetes; cirrhosis

• Registration Number: TCTR20200604001
• Lead Sponsor: Faculty of Medicine Siriraj Hospital, Mahidol University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2020-06-01
• Study Start: 2020-06-04
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 1061

Inclusion Criteria

1) patients had to be 20-80 years old
2) Diagnosed with T2D Using diagnostic criteria From the American Diabetes Association, (ADA) or self-reported medical history or physician note even or taking anti diabetic agents
3) the diagnosis of cirrhosis was diagnosed by histology or clinical features or radiological images
4) T2D was diagnosed before the onset of cirrhosis and HCC
5) T2D has been newly diagnosed with cirrhosis of various causes in the period from 2006-2014.

Exclusion Criteria

1) patients who underwent liver transplantation
2) patients were follow up at Siriraj hospital less than 5 years
3) diagnosis of cirrhosis along with HCC or diagnosed with HCC after diagnosis of cirrhosis in less than 1 year
4) incomplete clinical information.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of HCC in Type 2 DM with cirrhosis who were treated with Metformin 5 years after diagnosed with cirrhosis incidence of HCC patients

Secondary Outcome Measures

Name	Time	Method
The median survival of the HCC patients with Metformin exposure group Death 5-year survival rate, kaplan meier method